Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Ups China R&D Investment

publication date: Dec 13, 2007

Earlier this year, GlaxoSmithKline announced it would invest $40 million to establish a neurological R&D center in Shanghai’s Zhangjiang Hi-Tech Park. Now, GSK has revised those plans, becoming even more committed to its China R&D efforts: the company says it will spend $100 million by the end of 2008 on this same facility, which will have 1,000 staff members in place by the end of 2010. GSK was very emphatic about the importance of China to GSK. More details....

Stock Symbol: (NYSE: GSK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital